| A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis (NCT07465289) | UCB Biopharma SRL | 2026-07-27 |
| A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (NCT07725939) | UCB Biopharma SRL | 2026-07-27 |
| SLC6A1-NDD Prospective Longitudinal Natural History Study (NCT07531511) | UCB Biopharma SRL | 2026-07-21 |
| A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis (NCT07463521) | UCB Biopharma SRL | 2026-05-27 |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults (NCT07290036) | UCB Biopharma SRL | 2025-12-10 |
| Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis (NCT07246564) | UCB Biopharma SRL | 2025-12-01 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis (NCT07219420) | UCB Biopharma SRL | 2025-11-14 |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) (NCT06888193) | UCB Biopharma SRL | 2025-11-05 |
| A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants (NCT07220551) | UCB Biopharma SRL | 2025-10-23 |
| A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women (NCT06961747) | UCB Biopharma SRL | 2025-07-09 |
| A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants (NCT07020988) | UCB Biopharma SRL | 2025-06-12 |
| A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants (NCT06970301) | UCB Biopharma SRL | 2025-04-28 |
| A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa (NCT06921850) | UCB Biopharma SRL | 2025-04-07 |
| An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis (NCT06668181) | UCB Biopharma SRL | 2025-03-11 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants (NCT06716879) | UCB Biopharma SRL | 2024-12-06 |
| A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women (NCT06720714) | UCB Biopharma SRL | 2024-12-03 |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (NCT06617325) | UCB Biopharma SRL | 2024-11-21 |
| An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis (NCT06435312) | UCB Biopharma SRL | 2024-11-19 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis (NCT06624228) | UCB Biopharma SRL | 2024-10-21 |
| A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis (NCT06055959) | UCB Biopharma SRL | 2024-10-16 |
| An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis (NCT06540144) | UCB Biopharma SRL | 2024-10-08 |
| A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants (NCT06533475) | UCB Biopharma SRL | 2024-09-06 |
| A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis (NCT06471361) | UCB Biopharma SRL | 2024-08-27 |
| A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants (NCT06511076) | UCB Biopharma SRL | 2024-08-05 |
| A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants (NCT06555601) | UCB Biopharma SRL | 2024-07-31 |
| A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis (NCT06506916) | UCB Biopharma SRL | 2024-07-29 |
| A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (NCT06315322) | UCB Biopharma SRL | 2024-07-10 |
| A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants (NCT06315335) | UCB Biopharma SRL | 2024-07-01 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis (NCT06425549) | UCB Biopharma SRL | 2024-06-25 |
| A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis (NCT06149559) | UCB Biopharma SRL | 2024-06-14 |
| A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants (NCT06312566) | UCB Biopharma SRL | 2024-03-25 |
| A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease (NCT06055985) | UCB Biopharma SRL | 2023-11-17 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis (NCT06011733) | UCB Biopharma SRL | 2023-10-31 |
| A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B (NCT05845645) | UCB Biopharma SRL | 2023-05-31 |
| A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG) (NCT05681715) | UCB Biopharma SRL | 2023-04-17 |
| A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants (NCT05626439) | UCB Biopharma SRL | 2022-12-28 |
| A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome (NCT05643794) | UCB Biopharma SRL | 2022-12-21 |
| An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors (NCT05514873) | UCB Biopharma SRL | 2022-10-31 |
| An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease (NCT05543252) | UCB Biopharma SRL | 2022-08-29 |
| A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants (NCT05315947) | UCB Biopharma SRL | 2022-04-04 |
| A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (NCT05109234) | UCB Biopharma SRL | 2022-03-30 |
| A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants (NCT05292131) | UCB Biopharma SRL | 2022-03-17 |
| A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) (NCT05277571) | UCB Biopharma SRL | 2022-03-07 |
| A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures (NCT05076617) | UCB Biopharma SRL | 2022-02-03 |
| A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD) (NCT05063162) | UCB Biopharma SRL | 2022-02-02 |
| A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures (NCT05077904) | UCB Biopharma SRL | 2021-12-07 |
| A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis (NCT05067335) | UCB Biopharma SRL | 2021-10-21 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis (NCT05020249) | UCB Biopharma SRL | 2021-09-27 |
| A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis (NCT04875975) | UCB Biopharma SRL | 2021-09-27 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (NCT04666610) | UCB Biopharma SRL | 2021-07-29 |
| A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus (NCT04976322) | UCB Biopharma SRL | 2021-07-27 |
| A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) (NCT04867616) | UCB Biopharma SRL | 2021-06-09 |
| A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease (NCT04643483) | UCB Biopharma SRL | 2021-06-01 |
| A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (NCT04901195) | UCB Biopharma SRL | 2021-05-27 |
| A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects (NCT04882540) | UCB Biopharma SRL | 2021-05-19 |
| A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease (NCT04867642) | UCB Biopharma SRL | 2021-04-29 |
| A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy (NCT04857307) | UCB Biopharma SRL | 2021-04-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants (NCT04828343) | UCB Biopharma SRL | 2021-04-22 |
| A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis (NCT04718896) | UCB Biopharma SRL | 2021-04-06 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures (NCT04519645) | UCB Biopharma SRL | 2021-03-31 |
| A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures (NCT04715646) | UCB Biopharma SRL | 2021-03-11 |
| A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma (NCT04802746) | UCB Biopharma SRL | 2021-03-09 |
| Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants (NCT04782388) | UCB Biopharma SRL | 2021-03-04 |
| A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis (NCT04740814) | UCB Biopharma SRL | 2021-02-11 |
| A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants (NCT04705350) | UCB Biopharma SRL | 2021-01-11 |
| A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (NCT04596995) | UCB Biopharma SRL | 2021-01-06 |
| A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease (NCT04658186) | UCB Biopharma SRL | 2020-12-30 |
| A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment (NCT04627285) | UCB Biopharma SRL | 2020-12-28 |
| A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD) (NCT04651153) | UCB Biopharma SRL | 2020-12-14 |
| A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis (NCT04643457) | UCB Biopharma SRL | 2020-11-27 |
| A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy (NCT04658199) | UCB Biopharma SRL | 2020-11-16 |
| A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors (NCT04393298) | UCB Biopharma SRL | 2020-07-09 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (NCT04444466) | UCB Biopharma SRL | 2020-06-30 |
| A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (NCT04163016) | UCB Biopharma SRL | 2020-06-19 |
| A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (NCT04436640) | UCB Biopharma SRL | 2020-06-16 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (NCT04224688) | UCB Biopharma SRL | 2020-06-03 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (NCT04242498) | UCB Biopharma SRL | 2020-03-02 |
| A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil (NCT04283136) | UCB Biopharma SRL | 2020-02-24 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (NCT04242446) | UCB Biopharma SRL | 2020-02-19 |
| A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants (NCT04255862) | UCB Biopharma SRL | 2020-02-12 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (NCT04200456) | UCB Biopharma SRL | 2020-01-31 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (NCT04123795) | UCB Biopharma SRL | 2020-01-21 |
| Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (NCT04225871) | UCB Biopharma SRL | 2019-12-23 |
| A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome (NCT03992196) | UCB Biopharma SRL | 2019-12-03 |
| A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) (NCT04185415) | UCB Biopharma SRL | 2019-12-03 |
| A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis (NCT04124965) | UCB Biopharma SRL | 2019-10-29 |
| A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants (NCT04131517) | UCB Biopharma SRL | 2019-10-23 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury (NCT04335578) | UCB Biopharma SRL | 2019-10-21 |
| A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (NCT04053881) | UCB Biopharma SRL | 2019-08-21 |
| A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (NCT04051944) | UCB Biopharma SRL | 2019-08-21 |
| A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis (NCT04109976) | UCB Biopharma SRL | 2019-08-13 |
| A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (NCT04009499) | UCB Biopharma SRL | 2019-08-13 |
| A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis (NCT03971422) | UCB Biopharma SRL | 2019-06-03 |
| A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (NCT03325439) | UCB Biopharma SRL | 2019-05-07 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis (NCT03928704) | UCB Biopharma SRL | 2019-04-25 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis (NCT03928743) | UCB Biopharma SRL | 2019-04-25 |
| A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (NCT03895203) | UCB Biopharma SRL | 2019-04-03 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (NCT03896581) | UCB Biopharma SRL | 2019-03-28 |
| A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy (NCT03739840) | UCB Biopharma SRL | 2019-03-06 |
| A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause (NCT03728933) | UCB Biopharma SRL | 2018-12-20 |